| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/17/2001 | US6218364 Fluorinated neurokinin A antagonists |
| 04/17/2001 | US6218363 MHC peptides and methods of use |
| 04/17/2001 | US6218362 For therapy and prophylaxis of bacterial infections |
| 04/17/2001 | US6218361 Administering anti-angiogenic agent selected from consisting of agm 1470 and tnp-470 for inhibiting chronic allograft rejection with an organ transplant |
| 04/17/2001 | US6218360 Collagen based biomaterials and methods of preparation and use |
| 04/17/2001 | US6218359 Treating autoimmune, arthritic, tumor diseases |
| 04/17/2001 | US6218357 For use in decreasing blood cholesterol, in cosmetics, hydgine products and foods |
| 04/17/2001 | US6218181 Retroviral packaging cell line |
| 04/17/2001 | US6218180 Virion coding a toxic agent, cytokine and tumor suppressor; for the treatment of tumorous defects; antitumor agents |
| 04/17/2001 | US6218179 Nucleotide sequences coding human metallothionein regulatory sequences; for reducing ischemic injury to a cell exposed to hypoxic conditions |
| 04/17/2001 | US6218165 Protease with altered t-cell epitopes; prevents sensitization of individual to protein; detergents; treatment of wool to prevent felting; soaps; cosmetics; skin care |
| 04/17/2001 | US6218159 Amino acid sequence; bacteriostats; bactericides; antibiotics; diagnosis of infections; drug screening |
| 04/17/2001 | US6218157 Haloacetoacetate reductase, method for producing said enzyme, and method for producing alcohols using said enzyme |
| 04/17/2001 | US6218149 Altering affinity of antibody for antigen by deleting dna encoding a carbohydrate recognition site from variable domain of antibody, expressing mutagenized gene, measuring affinity of altered antibody and comparing to control |
| 04/17/2001 | US6218148 DNS encoding stem cell factor |
| 04/17/2001 | US6218144 Nucleic acid encoding a cos2 protein of defined amino acid sequence involved in hedgehog signaling pathway; anticarcinogenic agents |
| 04/17/2001 | US6218136 Methods of the identification of pharmaceutically active compounds |
| 04/17/2001 | US6218131 Diagnosis by detecting presence of protein of defined amino acid sequence in sample |
| 04/17/2001 | US6218120 Methods for detecting human methylene tetrahydrofolate reductase allelic variants |
| 04/17/2001 | US6218113 Human protein kinase C inhibitor |
| 04/17/2001 | US6218109 Mammalian checkpoint genes and proteins |
| 04/17/2001 | US6218103 Screening method by infecting cell having us3 gene under control of immediate early promoter with herpes virus lacking functional us3 gene, contacting with test compound, incubating for viral replication, comparing pathology with control |
| 04/17/2001 | US6217914 Ascorbic acid composition and method for treatment of aging or damaged skin |
| 04/17/2001 | US6217893 Sustained-release compositions and method for preparing same |
| 04/17/2001 | US6217886 Materials and methods for making improved micelle compositions |
| 04/17/2001 | US6217882 Inserting heterogeneity nucleotide sequence |
| 04/17/2001 | US6217879 Peptide mixture; hypotensive agents |
| 04/17/2001 | US6217870 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor |
| 04/17/2001 | US6217866 Antitumor agents mixture |
| 04/17/2001 | US6217864 Method for targeted degradation of intracellular proteins in vivo or ex vivo |
| 04/17/2001 | US6217863 Rationally designed polysaccharide lyases derived from heparinase I |
| 04/17/2001 | US6217862 Isolated polypeptide |
| 04/17/2001 | US6217861 pneumococcus; use as drug target for drug screening antibiotics |
| 04/17/2001 | US6217860 Supplying adenoviral vector into tumor |
| 04/17/2001 | US6217858 Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| 04/17/2001 | US6217857 Isolated polypeptide |
| 04/17/2001 | CA2163107C Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
| 04/17/2001 | CA2156742C Phosphonomethyldipeptides |
| 04/17/2001 | CA2152267C Difluoro-pentapeptide derivative anti-inflammatory agents |
| 04/17/2001 | CA2125985C Stem cell inhibiting proteins |
| 04/17/2001 | CA2110670C Spiro piperidines and homologs which promote release of growth hormone |
| 04/17/2001 | CA2064473C Chimeric amino acids and peptides containing these analogues |
| 04/12/2001 | WO2001025489A2 Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer |
| 04/12/2001 | WO2001025486A1 Methods for identifying rna binding compounds |
| 04/12/2001 | WO2001025465A1 Adeno-associated viruses and uses thereof |
| 04/12/2001 | WO2001025464A1 Materials and methods for simplified aav production |
| 04/12/2001 | WO2001025450A1 Use of soluble costimulatory factor for tumor immuno-gene therapy |
| 04/12/2001 | WO2001025446A1 Dna encoding prost 07 polypeptide |
| 04/12/2001 | WO2001025445A1 Fibrinolytically active polypeptide |
| 04/12/2001 | WO2001025442A1 Dna polymerase lambda and uses thereof |
| 04/12/2001 | WO2001025441A2 Tumour-specific vector for gene therapy |
| 04/12/2001 | WO2001025440A1 C3 binding polypeptide of streptococcus agalactiae, group b streptococcus |
| 04/12/2001 | WO2001025438A2 Ifn-alpha homologues |
| 04/12/2001 | WO2001025437A2 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | WO2001025436A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 04/12/2001 | WO2001025435A2 In vivo treatment of joint disease using interleukin-1 receptor antagonists |
| 04/12/2001 | WO2001025434A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | WO2001025433A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | WO2001025429A2 Hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use |
| 04/12/2001 | WO2001025428A1 A novel human leptin homolog |
| 04/12/2001 | WO2001025427A1 Shear stress-response dna |
| 04/12/2001 | WO2001025422A2 Antisense compositions and cancer-treatment methods |
| 04/12/2001 | WO2001025414A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 04/12/2001 | WO2001025413A1 Use of a context-dependent functional entity to enhance the efficacy of an agent |
| 04/12/2001 | WO2001025410A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 04/12/2001 | WO2001025409A1 Novel human lipase proteins, nucleic acids encoding them, and uses of both of these |
| 04/12/2001 | WO2001025408A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 04/12/2001 | WO2001025405A1 C-myc antisense-treated hematopoietic stem cell composition and method |
| 04/12/2001 | WO2001025404A1 Methods for inhibiting osteoclast formation or methods for inhibiting bone resorption |
| 04/12/2001 | WO2001025400A2 Compositions and methods for modulating atp-binding cassette transmembrane reporter protein expression |
| 04/12/2001 | WO2001025397A2 Compositions and methods for tumor-targeted delivery of effector molecules |
| 04/12/2001 | WO2001025390A2 Water unstable foam compositions |
| 04/12/2001 | WO2001025282A1 Il13 mutants |
| 04/12/2001 | WO2001025279A1 Cd29 pig protein, nucleic acid coding for said protein and the applications thereof |
| 04/12/2001 | WO2001025277A1 Single-chain antagonist polypeptides |
| 04/12/2001 | WO2001025275A1 Regulatory/unfolding peptides of ezrin |
| 04/12/2001 | WO2001025273A2 Compositions and methods for wt1 specific immunotherapy |
| 04/12/2001 | WO2001025271A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025268A1 Human seizure related proteins |
| 04/12/2001 | WO2001025267A2 Improved ricin-like toxins for treatment of cancer |
| 04/12/2001 | WO2001025266A1 Uroguanylin as an intestinal cancer inhibiting agent |
| 04/12/2001 | WO2001025265A1 Metal-binding compounds and uses therefor |
| 04/12/2001 | WO2001025264A2 Substituted phosphinate based peptide derivatives |
| 04/12/2001 | WO2001025257A2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 04/12/2001 | WO2001025252A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | WO2001025249A1 Compositions and methods for identifying polypeptides and nucleic acid molecules |
| 04/12/2001 | WO2001025248A2 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | WO2001025188A1 Novel carbamates and ureas |
| 04/12/2001 | WO2001025170A1 N-SUBSTITUTED DIALKYL α-AMINO ACIDS FOR USE AS AMINO PROTECTING GROUPS |
| 04/12/2001 | WO2001024842A2 Hybrid matrices and hybrid matrix mixtures |
| 04/12/2001 | WO2001024832A2 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/12/2001 | WO2001024831A2 Polymer stabilized neuropeptides |
| 04/12/2001 | WO2001024828A2 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 04/12/2001 | WO2001024827A2 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 04/12/2001 | WO2001024823A1 Cd40 antagonist for treating psoriasis |
| 04/12/2001 | WO2001024821A1 Nell-1 enhanced bone mineralization |
| 04/12/2001 | WO2001024819A1 YsxC |
| 04/12/2001 | WO2001024817A2 Pharmaceutical compositions of fibrinolytic agent |
| 04/12/2001 | WO2001024816A2 Compositions and methods relating to the inhibition of casomorphin and gluteomorphin |